NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $151K rose 1158.3% year over year, ahead of the +43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 86.4% from the prior quarter. Over 3 fiscal years it compounded at -60.2% a year.
Context
- Stock-based compensation amounted to 18.6% of revenue in FY2025.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1158.3% holds above the trailing-twelve-month pace of +43.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 228K USD
- Year-over-year change
- -53.1%
- 4-year CAGR
- -58.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 228K | -53.1% |
| FY2024 | 2024-12-31 | 486K | +25.6% |
| FY2023 | 2023-12-31 | 387K | -89.3% |
| FY2022 | 2022-12-31 | 3.63M | -53.4% |
| FY2021 | 2021-12-31 | 7.79M | — |
Stock-Based Compensation vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 stock-based compensation of $367K is the smallest of the 9 companies compared; the peer median is $3.62M.
- Its year-over-year change of +43.4% is the highest of 9, against a peer median of -37.2%.
- Stock-based compensation amounts to 16.0% of revenue for NRXP, versus a peer median of 18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.5M | -20.7% | -26.5% | 8.9% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $3.45M | -44.6% | -20.7% | 10.6% | |
| LTM Mar 2026 | $2.72M | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| LTM Mar 2026 | $1.82M | +13.4% | — | 128.8% | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding NRXP) | $3.62M | -37.2% | -13.8% | 18.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.79M | 3.63M | 387K | 486K | 228K |
| Change in Working Capital | (4.9M) | 699K | 5.16M | 5.29M | 1.41M |
| Accounts Receivables | 831K | 0 | 0 | 0 | 48K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (19K) | (1.61M) | 2.66M | (5.22M) | 113K |
| Other Working Capital | (5.71M) | 2.31M | 2.51M | 10.51M | 1.25M |
| Other Non-Cash Items | 52.47M | (4.33M) | 2.94M | 8.71M | 12.73M |
| Operating Cash Flow | (37.7M) | (39.76M) | (21.66M) | (10.64M) | (14.11M) |
| Capital Expenditures | (7K) | (10K) | (3K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (2.38M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (432K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7K) | (10K) | (3K) | 0 | (2.81M) |
| Debt Repayment | (1.28M) | 9.5M | (3.09M) | (1.5M) | 7.42M |
| Common Stock Issued | 36.98M | 22.7M | 8.12M | 5.91M | 15.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.75M | 10K | 0 | 3.07M | 0 |
| Financing Cash Flow | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.75M | (7.55M) | (15.46M) | (3.15M) | 6.35M |
| Free Cash Flow | (37.71M) | (39.77M) | (21.66M) | (10.64M) | (14.11M) |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.